Laura Smit

Laura Smit

Auto-generated profile, based on publicly available information

Laura Smit

Department of Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in The International Journal of Biological Markers
Verified
Journal Article
Closed access
LSL.H.M. Smit
L.H.M. Smit
CKC.M. Korse
C.M. Korse
JBJ.M.G. Bonfrer
J.M.G. Bonfrer
Background: S-100B determination has been shown to be clinically useful in the management of melanoma patients. After the development of a test for determination of the isoforms S100-A1B and S100-BB in serum (S-100B), several sensitive assays for the detection of serum S-100B have become available. We compared four S-100B assays, two automated (LIAISON®Sangtec®100 and Elecsys®S100) and two manual ones (Sangtec®100 ELISA and CanAg S100 EIA), with respect to clinical data, reference values and correlation. Methods: In a total of 280 samples from 155 melanoma patients and 98 healthy individuals S-100B values were measured simultaneously with the different assays. Results: The inter and intra coefficients of variation were best for the automated assays. The functional sensitivity of both manual assays was 0.15 μg/L. Method comparison revealed satisfactory correlation coefficients of 0.9 or higher, but the slopes ranged from 0.29 to 3.36. Except for the Sangtec®100 ELISA, the linearity between the assays was acceptable. The overall sensitivity for melanoma ranged from 37% (Elecsys®S100) to 47% (LIAISON®Sangtec®100) and the sensitivity increased with stage. ROC curves showed the best accuracy for the LIAISON®Sangtec®100 assay. Conclusions: All assays gave satisfactory results, but it is advisable to improve the performance of the manual assays for better sensitivity. Agreement about an international reference standard is needed.

1 February 2005 in European Journal of Cancer
Verified
Journal Article
Closed access
LSLéonie H.M. Smit
Léonie H.M. Smit
CKCatharina M. Korse
Catharina M. Korse
AHAugustinus A.M. Hart
Augustinus A.M. Hart
JBJohannes M.G. Bonfrer
Johannes M.G. Bonfrer
JHJohn B.A.G. Haanen
John B.A.G. Haanen
GGGijsbert C. de Gast
Gijsbert C. de Gast

1 January 2005 in The International Journal of Biological Markers
Verified
Journal Article
Closed access
LSL.H.M. Smit
L.H.M. Smit
CKC.M. Korse
C.M. Korse
JBJ.M.G. Bonfrer
J.M.G. Bonfrer
S-100B determination has been shown to be clinically useful in the management of melanoma patients. After the development of a test for determination of the isoforms S100-A1B and S100-BB in serum (S-100B), several sensitive assays for the detection of serum S-100B have become available. We compared four S-100B assays, two automated (LIAISON Sangtec 100 and Elecsys S100) and two manual ones (Sangtec 100 ELISA and CanAg S100 EIA), with respect to clinical data, reference values and correlation. In a total of 280 samples from 155 melanoma patients and 98 healthy individuals S-100B values were measured simultaneously with the different assays. The inter and intra coefficients of variation were best for the automated assays. The functional sensitivity of both manual assays was 0.15 microg/L. Method comparison revealed satisfactory correlation coefficients of 0.9 or higher, but the slopes ranged from 0.29 to 3.36. Except for the Sangtec 100 ELISA, the linearity between the assays was acceptable. The overall sensitivity for melanoma ranged from 37% (Elecsys S100) to 47% (LIAISON Sangtec 100) and the sensitivity increased with stage. ROC curves showed the best accuracy for the LIAISON Sangtec 100 assay. All assays gave satisfactory results, but it is advisable to improve the performance of the manual assays for better sensitivity. Agreement about an international reference standard is needed.

1 February 2022 in Oral Oncology
Verified
Journal Article
Open access
SWStijn van Weert
Stijn van Weert
MVMatthijs Valstar
Matthijs Valstar
BLBirgit Lissenberg-Witte
Birgit Lissenberg-Witte
Elisabeth BloemenaElisabeth Bloemena
Elisabeth Bloemena
LSLaura Smit
Laura Smit
CLC.REné Leemans
C.REné Leemans
The aim was to analyse prognosticators in acinic cell carcinoma (AciCC) in two head and neck referral centers in Amsterdam, the Netherlands. Eighty- nine cases of AciCC treated between 1979 and 2016 were retrospectively reviewed. Five, - 10 -and 20- year estimates of survival were executed as well as univariate analysis of prognosticators. The majority of AciCC were T1-T2; 89%. Two percent had nodal disease (2%). The most affected organ was the parotid gland (84%) with a female preponderance (67%). Mean age was 52 years with most cases diagnosed in the fourth to sixth decade. The majority of patients received adjuvant radiotherapy. Elective neck dissection (END) in the N0 neck showed no metastases. High grade transformation (HGT) was found in 21% of cases. Median follow up was 101.9 months. Median time to recurrence was 26 months. Nine patients developed distant metastases (DM) of whom 6 had HGT-AciCC. Median survival with DM was 7 months. Five,- ten -and twenty- year estimates were 84%, 81% and 81% for recurrence free survival respectively. Negative clinical features were advanced stage disease and tumour size > 2.6 cm. Negative histological features were a high mitotic rate, HGT, close and involved surgical margins and necrosis. AciCC- HGT excluded- of the head and neck has an excellent prognosis and shows acceptable long term results. END can be considered as part of the standard treatment due to the relative high incidence of HGT- AciCC and low accuracy of cytology.

21 May 2018 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
ABAnn-Jean C. C. Beck
Ann-Jean C. C. Beck
PLPeter J. F. M. Lohuis
Peter J. F. M. Lohuis
AAAbrahim Al-Mamgani
Abrahim Al-Mamgani
LSLaura A. Smit
Laura A. Smit
WKWillem M. C. Klop
Willem M. C. Klop

17 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
HHHedda J. van der Hulst
Hedda J. van der Hulst
JVJoris L. Vos
Joris L. Vos
RTRenaud Tissier
Renaud Tissier
LSLaura A. Smit
Laura A. Smit
RMRoland Martens
Roland Martens
JCJonas Castelijns
Jonas Castelijns
Background: Neoadjuvant immune checkpoint blockade (ICB) prior to surgery may induce early pathological responses in head and neck squamous cell carcinoma (HNSCC) patients. Routine imaging parameters fail to diagnose these responses early on. Magnetic resonance (MR) diffusion-weighted imaging (DWI) has proven to be useful for detecting HNSCC tumor mass after (chemo)radiation therapy. METHODS: 32 patients with stage II–IV, resectable HNSCC, treated at a phase Ib/IIa IMCISION trial (NCT03003637), were retrospectively analyzed using MR-imaging before and after two doses of single agent nivolumab (anti-PD-1) (n = 6) or nivolumab with ipilimumab (anti-CTLA-4) ICB (n = 26). The primary tumors were delineated pre- and post-treatment. A total of 32 features were derived from the delineation and correlated with the tumor regression percentage in the surgical specimen. Results: MR-DWI data was available for 24 of 32 patients. Smaller baseline tumor diameter (p = 0.01−0.04) and higher sphericity (p = 0.03) were predictive of having a good pathological response to ICB. Post-treatment skewness and the change in skewness between MRIs were negatively correlated with the tumor’s regression (p = 0.04, p = 0.02). Conclusion: Pre-treatment DWI tumor diameter and sphericity may be quantitative biomarkers for the prediction of an early pathological response to ICB. Furthermore, our data indicate that ADC skewness could be a marker for individual response evaluation.